Cingulate Inc. (NASDAQ:CING – Get Free Report)’s share price fell 12% during trading on Wednesday . The stock traded as low as $0.26 and last traded at $0.27. 743,704 shares were traded during mid-day trading, an increase of 85% from the average session volume of 402,880 shares. The stock had previously closed at $0.31.
Cingulate Stock Down 13.7 %
The firm has a 50 day moving average of $0.47 and a 200 day moving average of $0.99.
Cingulate (NASDAQ:CING – Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($2.20) by $1.60.
Cingulate Company Profile
Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.
Featured Articles
- Five stocks we like better than Cingulate
- Compound Interest and Why It Matters When Investing
- The Cannabis Sector: Profitability Takes Center Stage
- What is the Nikkei 225 index?
- Amazon’s Stock Plunge: Is a Prime Buying Opportunity Knocking?
- Airline Stocks – Top Airline Stocks to Buy Now
- Buy the Dip in e.l.f. Beauty: Analysts Point to a New High
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
